Key facts
- Cytocares Technology’s last known valuation is $103.6M (Oct 2025).
- It has raised $24.1M; the latest was Later Stage VC ($9.5M) in Oct 2025.
- Notable investors include Shenzhen Capital Group, Jolmo Investment, Shenzhen Guozhong Venture Capital Management, Tailong VC, Prosperico Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Cytocares Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Cytocares Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cytocares Technology
Researcher and developer of innovative macromolecule drugs for tumor immunotherapy, the company is mainly focused on the research and development of innovative drugs for immunotherapy of hematological tumors and solid tumors, providing clients with potential treatments and drugs to treat tumors.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2015
- Website
- cytocares.com/
- Ownership
- Privately Held (backing)
Cytocares Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cytocares Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cytocares Technology in its N-PORT filings yet. We sweep new filings monthly.